Compare Mesoblast Limited (MESO) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs McCormick & Company, Incorporated — how do they compare? Mesoblast Limited trades at $16.41 (market cap $2.17B), while McCormick & Company, Incorporated trades at $52.38 (market cap $14.04B). The key difference: McCormick & Company, Incorporated is far larger — about 6.5× Mesoblast Limited's market cap, and McCormick & Company, Incorporated pays a 3.68% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | MKC | |
|---|---|---|
Market Cap | $2.17B | $14.04B |
Sector | Technology | Consumer Staples |
52-Week High | $20.96 | $72.81 |
52-Week Low | $12.88 | $45.60 |
Enterprise Value | $2.17B | $18.65B |
Dividend Yield | — | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
MKC trades at $52.26, up 1.08% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong profitability with a 21.91% net income margin and a low P/E of 8.6, suggesting potential undervaluation. Recent Q2 2026 earnings beat expectations, and the pending Unilever Foods deal is a key strategic focus. Cash flow from operations remains robust at $962.2 million for 2025, though net cash flow was negative $90.2 million due to financing activities.
The outlook is mixed; analyst consensus is a buy with a $59.67 price target, implying 14% upside, but technicals and modest organic growth pose risks. The transformative Unilever deal offers growth potential, yet execution risks and competitive pressures in consumer segments warrant caution. Debt reduction trends are positive, with debt-to-asset ratio improving to 30.34% in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
